Metronomic chemotherapy in progressive pediatric malignancies: Old drugs in new package

Indian Journal of Pediatrics

Volumn 79, Issue 12, 2012, Pages 1617-1622

  Bahl, Ankur ^a   Bakhshi, Sameer ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Drugs; Metronomic chemotherapy; Pediatric malignancy

Indexed keywords

ANGIOGENESIS INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETOPOSIDE; METHOTREXATE; PACLITAXEL; RETINOIC ACID; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CELL CYCLE ARREST; CHILDHOOD CANCER; DENDRITIC CELL; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; METRONOMIC CANCER CHEMOTHERAPY; METRONOMIC DRUG ADMINISTRATION; MULTIPLE MYELOMA; NEOPLASM; NEPHROBLASTOMA; NONHUMAN; ONCOLOGICAL PARAMETERS; PATIENT COMPLIANCE; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; RETINOBLASTOMA; SECOND CANCER; TUMOR DORMANCY; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEDIATRICS;

EID: 84878445416     PISSN: 00195456     EISSN: 09737693     Source Type: Journal    
DOI: 10.1007/s12098-012-0759-z     Document Type: Article

References (45)

1. Steen RG. What is cancer? In Steen RG, Mirro J, eds. Childhood cancer: A handbook from St. Jude Children's Research Hospital, Perseus Publishing Cambridge; 2000. pp. 3-10.
2. Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, Provincial/Terretorial Cancer Registries, and Health Canada. Canadian Cancer Statistics 2004.
3. Canadian Cancer Statistics 2000. Cancer in Children aged 0-19 yrs. National Cancer Institute of Canada: Cancer Statistics 2000, Toronto, Canada, 2000. Accessed June 22nd, 2005. Online: http://www.cancer.ca/stats2000.childe. htm
4. Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull. 2004;27:599-605.
5. Fidler IJ, Ellis LM. Chemotherapeutic drugs: more really is not better. Nat Med. 2000;6:500-2.
6. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays. 1991;13:31-6.
7. Kerbel RS. A cancer therapy resistant to resistance. Nature. 1997;390:335-6.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-6.
9. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 1999;58:17-38.
10. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2001;2:278-89.
11. Miller KD, Sweeney CJ, Sledge Jr GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19:1195-206.
12. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000;60:1388-93.
13. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15-24.
14. Browder T, Butterfield CE, Kräling, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res. 2000;60:1878-86.
15. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-36.
16. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-8.
17. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I. The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz). 2008;56:181-91.
18. Kono K, Kawaida H, Takahashi A, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 2006;55:1064-71.
19. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336-44.
20. Loeffler M, Krüger JA, Reisfeld RA. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res. 2005;65:5027-30.
21. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4 (+) 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862-8.
22. Matsushima H, Takashima A. Cyclophosphamide, DCs, and Tregs. Blood. 2010;115:4322-4.
23. Tanaka H, Matsushima H, Mizumoto N, Takashima A. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res. 2009;69:6978-86.
24. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-10.
25. Audia S, Nicolas A, Cathelin D, et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:A phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+T lymphocytes. Clin Exp Immunol. 2007;150:523-30.
26. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-16.
27. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-11.
28. Gupta RA, Dubois RN. Combinations for cancer prevention. Nat Med. 2000;6:974-5.
29. Hsueh CT, Chiu CF, Kelsen DP, Schwartz GK. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother Pharmacol. 2000;45:389-96.
30. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-5.
31. Yoneda T, Alsina MA, Chavez JB, Bonewald L, Nishimura R, Mundy GR. Evidence that tumour necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcaemia, and leukocytosis in a human tumour in nude mice. J Clin Invest. 1991;87:977-85.
32. Cabral FR. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol. 1983;97:22-9.
33. Wong NS, Buckman RA, Clemons M, et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol. 2010;28:723-30.
34. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26:76-82.
35. Sarmiento R, Gasparini G. Antiangiogenic metronomic chemotherapy. Onkologie. 2008;31:161-2.
36. Patil V, Noronha V, D'cruz AK, Banavali SD, Prabhash K. Metronomic chemotherapy in advanced oral cancers. J Cancer Res Ther. 2012;8:S106-10.
37. Sterba J, Pavelka Z, Slampa P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma. 2002;49:117-20.
38. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27:573-81.
39. Fousseyni T, Diawana M, Pasquier E, André N. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01. J Pediatr Hematol Oncol. 2011;33:31-4.
40. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel SA. pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol. 2006;28:720-8.
41. Choi LM, Rood B, Kamani N, et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer. 2008;50:970-5.
42. Minturn JE, Janss AJ, Fisher PG, et al. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer. 2011;56:39-44.
43. Bocci G, Tuccori M, Emmenegger U, et al. Cyclophosphamide methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol. 2005;16:1243-52.
44. De Vita S, De Matteis S, Laurenti L, et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol. 2005;84:760-2.
45. Rome A, André N, Scavarda D, et al. Metronomic chemotherapy induced bilateral subdural hematoma in a child with meningeal carcinomatosis. Pediatr Blood Cancer. 2009;53:246-7.